BCCA Protocol Summary for Anagrelide as Second-line Treatment of Thrombocytosis Related to Myeloproliferative Disorders

Protocol Code  
LKANAG

Tumour Group  
Leukemia/BMT

Contact Physician  
Dr. Donna Hogge

ELIGIBILITY:
- myeloproliferative disorder
- platelet count of either: greater than $400 \times 10^9/L$ with symptoms greater than $1000 \times 10^9/L$ without symptoms
- inadequate response to or intolerance of hydroxyurea and/or interferon
- May be used in combination with busulfan, dexamethasone, hydroxyUREA, interferon or melphalan

EXCLUSIONS:
- Use with great care in patients with heart disease.
- Use with caution in patients with renal and /or hepatic impairment.
- Do not use during pregnancy

TESTS:
- CBC, platelets, differential
  - baseline
  - q1-2 weeks during dosage titration
  - q1-3 months during maintenance
- Urea, creatinine, electrolytes, bilirubin, AST, alkaline phosphatase
  - baseline
  - regularly for patients with renal and/or hepatic impairment

PREMEDICATIONS:
none

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>anagrelide</td>
<td>0.5 mg qid starting dose, adjust according to platelet count</td>
<td>PO</td>
</tr>
<tr>
<td></td>
<td>Usual maintenance dose 1 to 4 mg daily in divided doses (bid to qid)</td>
<td></td>
</tr>
</tbody>
</table>
In patients with satisfactory response, continue therapy indefinitely.

**DOSE MODIFICATIONS:**
none except titration to control platelet count

**PRECAUTIONS:**
1. **Headache:** Occurs in about 30% of patients; generally mild but can be more severe. Treat with acetaminophen prn.
2. **Palpitations:** Occur in about 25% of patients; may require discontinuation of anagrelide.
3. **Diarrhea:** Occurs in about 25% of patients. Supportive treatment involves adequate hydration, ingestion of low fibre foods in small amounts at frequent intervals.
4. **Fluid retention:** Occurs in about 20% of patients. Supportive treatment involves elevation of the feet and avoidance of tight clothing.

Call Dr. Donna Hogge or tumour group delegate at (604) 875-4337 with any problems or questions regarding this treatment program.

Date activated: 01 May 2001

Date revised: 1 Jun 2016 (Class II registration deleted)

**References:**
7. Anagrelide Product Monograph.